David D Stenehjem
Overview
Explore the profile of David D Stenehjem including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
470
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Murugappan M, King-Kallimanis B, Bhatnagar V, Kanapuru B, Farley J, Seifert R, et al.
J Geriatr Oncol
. 2023 Dec;
15(2):101681.
PMID: 38104480
Introduction: Frailty assessments may help to identify patients at highest risk for treatment-related toxicity, early treatment discontinuation due to toxicity, and death in Multiple Myeloma. We aimed to compare the...
2.
Aby E, Shen T, Murugappan M, Stenehjem D, Leventhal T
Hepatol Commun
. 2023 Aug;
7(8).
PMID: 37534941
Background And Aims: Hepatic encephalopathy (HE) is associated with significant morbidity and mortality for those with cirrhosis. Despite the known benefits of rifaximin use for HE, treatment retention remains low....
3.
Murugappan M, King-Kallimanis B, Bhatnagar V, Kanapuru B, Farley J, Seifert R, et al.
Qual Life Res
. 2023 Mar;
32(8):2281-2292.
PMID: 36935467
Purpose: The objective of this retrospective study was to determine the feasibility of measuring frailty using patient responses to relevant EORTC QLQ-C30 items as proxy criteria for the Fried Frailty...
4.
Ilham S, Willis C, Kim K, Chung K, Wood B, Tan M, et al.
BMC Cancer
. 2023 Jan;
23(1):33.
PMID: 36624408
Background: Diminished immune defense plays an important role in cancer development. Cancer risk in immunocompromised patients may differ. Identifying individuals with elevated cancer risk can inform strategies for routine cancer...
5.
Pokorny R, Stenehjem D, Gilreath J
J Oncol Pharm Pract
. 2022 Feb;
28(4):916-923.
PMID: 35132891
Objective: Oral tyrosine kinase inhibitors (TKIs) are first line therapy for chronic myeloid leukemia (CML). A complete cytogenetic response (CCyR) correlates with increased overall survival, however only 66%-88% of patients...
6.
Olander M, Waring S, Stenehjem D, Taran A, Ranelli P, Brown J
Innov Pharm
. 2021 May;
9(2):1-12.
PMID: 34007697
Background: Considerable progress has been made in the way of pharmacogenetic research and the development of clinical recommendations; however, its implementation into clinical practice has been slower than anticipated. We...
7.
Biltaji E, Walker B, Au T, Rivers Z, Ose J, Li C, et al.
Cancer Epidemiol Biomarkers Prev
. 2021 Apr;
30(6):1106-1113.
PMID: 33849967
Background: Inherited genetic variants can modify the cancer-chemopreventive effect of aspirin. We evaluated the clinical and economic value of genotype-guided aspirin use for colorectal cancer chemoprevention in average-risk individuals. Methods:...
8.
Brown J, Macdonald D, Yapel A, Luczak T, Hanson A, Stenehjem D
Pharmacogenomics
. 2021 Jan;
22(4):203-212.
PMID: 33470873
Pharmacogenetic (PGx) implementation has lagged behind the development of drug/gene pair guidelines. This was a prospective study assessing the integration of PGx through medication therapy management in an outpatient clinic....
9.
Stenehjem D, Telford C, Unni S, Bauer H, Sainski A, Deka R, et al.
Breast Cancer Res Treat
. 2021 Jan;
186(3):839-850.
PMID: 33389410
Main Purpose: Germline BRCA mutations (BRCAm) strongly influence the risk of developing breast cancer. This study aimed to understand the role of BRCAm testing in affected individuals and to assess...
10.
Stenehjem D, Lubinga S, Gupte-Singh K, Zhang Y, Le T, Penrod J, et al.
Clin Lung Cancer
. 2020 Nov;
22(1):e35-e47.
PMID: 33187914
Background: In phase 3 clinical trials, nivolumab prolonged overall survival (OS) compared to chemotherapy in patients with previously treated advanced non-small-cell lung cancer (NSCLC). This retrospective real-world study evaluated OS...